Vascular endothelial growth factor levels in ascites between chemonaive and chemotreated patients

Yonsei Medical Journal

Volumn 49, Issue 3, 2008, Pages 429-435

  Lee, Hae Kyung ^a   Chae, Hiun Suk ^a,b   Kim, Jin Soo ^a   Kim, Hyung Keun ^a   Cho, Young Seok ^a   Rho, Sang Young ^a   Kang, Jin Hyoung ^a   Cho, Seok Goo ^a   Jang, Hong Seok ^a   Han, Kyungja ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Carbohydrate antigen 19 9; Carcinoembryonic antigen; Chemotherapy; Malignant ascites; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CAPECITABINE; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; METHOTREXATE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; TUMOR MARKER; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASCITES FLUID CYTOLOGY; ASCITES HEPATOMA; ASCITES TUMOR; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; HUMAN; MALE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASCITES; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 48649107068     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2008.49.3.429     Document Type: Article

References (30)

1. Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med 2001;161:2733-7.
2. Colli A, Buccino G, Cocciolo M, Parravicini R, Mariani F, Scaltrini G. Diagnostic accuracy of fibronectin in the differential diagnosis of ascites. Cancer 1986;58:2489-93.
3. Sevinc A, Sari R, Fadillioglu E. The utility of lactate dehydrogenase isoenzyme pattern in the diagnostic evaluation of malignant and nonmalignant ascites. J Natl Med Assoc 2005;97:79-84.
4. Yildirim B, Sari R, Isci N. Patients with spontaneous bacterial peritonitis, and mlignant and cirrhotic ascites. J Natl Med Assoc 2005;97:276-80.
5. Siddiqui RA, Kochhar R, Singh V, Rajwanshi A, Goenka MK, Metha SK. Evaluation of fibronectin as a marker of malignant ascites. J Gastroenterol Hepatol 1992;7:161-4.
6. Rana SV, Babu SG, Kocchar R. Usefulness of ascitic fluid cholesterol as a marker for malignant ascites. Med Sci Monit 2005;11:136-42.
7. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999;6:373-8.
8. Dong WG, Sun XM, Yu BP, Luo HS, Yu JP. Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World J Gastroenterol 2003;9:2596-600.
9. Abramov Y, Anteby SO, Fasouliotis SJ, Barak V. Markedly elevated levels of vascular endothelial growth factor, fibroblast growth factor, and interleukin 6 in Meigs syndrome. Am J Obstet Gynecol 2001;184: 354-5.
10. Sun XM, Dong WG, Yu BP, Luo HS, Yu JP. Clinical significance of detecting VEGF, CD44v6, MMP-2 and MMP-9 in malignant ascites. Ai Zheng 2004;23:85-9.
11. Nascimento I, Schaer R, Lemaire D, Freire S, Paule B, Carvalho S, et al. Vascular endothelial growth factor (VEGF) levels as a tool to discriminate between malignant and nonmalignant ascites. APMIS 2004;112: 585-7.
12. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85:178-87.
13. Kuwahara K, Sasaki T, Kobayashi K, Noma B, Serikawa M, Iiboshi T, et al. Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites. Oncol Rep 2004;11:73-80.
14. Manenti L, Riccardi E, Marchini S, Naumova E, Floriani I, Garofalo A, et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther 2005;4:715-25.
15. Keyes K, Cox K, Treadway P, Mann L, Shih C, Faul MM, et al. An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res 2002;62:5597-602.
16. Lissoni P, Fugamalli E, Malugani F, Ardizzoia A, Secondino S, Tancini G, et al. Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer. Int J Biol Markers 2000;15:308-11.
17. Fernandes LC, Kim SB, Saad SS, Matos D. Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer. World J Gastroenterol 2006;12:3891-4.
18. Lowe D, Lee J, Schade R, Chaudhary A. Patient with markedly elevated CA 19-9 not associated with malignancy. South Med J 2006;99:306-8.
19. Nowak J, Jakubowska D, Wiczkowski A, Sprzaczkowska K, Stechly T, Zmudzińs W, et al. Carbohydrate antigens CA 19-9, CA 242, CA 50 in liver diseases. Wiad Lek 1998;51:484-91.
20. Trapé J, Molina R, Sant F. Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumour Biol 2004;25:276-81.
21. Chen SJ, Wang SS, Lu CW, Chao Y, Lee FY, Lee SD, et al. Clinical value of tumour markers and serum-ascites albumin gradient in the diagnosis of malignancy-related ascites. J Gastroenterol Hepatol 1994;9:396-400.
22. Cascinu S, Del Ferro E, Barbanti I, Ligi M, Fedeli A, Catalano G. Tumor markers in the diagnosis of malignant serous effusions. Am J Clin Oncol 1997;20: 247-50.
23. Miles LE, Hales CM. Labelled antibodies and immunological assay systems. Nature 1968;219:186-9.
24. Denstman F, Rosen L, Khubchandani IT, Sheets JA, Stasik JJ, Reither RD. Comparing predictive decision rules in postoperative CEA monitoring. Cancer 1986;58: 2089-95.
25. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 1983;29:549-52.
26. Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972;77:507-13.
27. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: World Health Organization; 1979.
28. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47: 207-14.
29. Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998;34:2041-5.
30. Loewenstein MS, Rittgers RA, Feinerman AE, Kupchik HZ, Marcel BR, Koff RS, et al. Carcinoembryonic antigen assay of ascites and detection of malignancy. Ann Intern Med 1978;88:635-8.